Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia.
Waldenstrom's macroglobulinemia is an indolent B-cell malignancy that is characterized by high levels of IgM paraprotein production and is incurable with standard chemotherapy. Iodine 131I-Tositumomab (iodine-131-labeled murine anti-CD20 monoclonal antibody; Bexxar) is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy refractory, CD20-positive, low grade or transformed B-cell non-Hodgkin's lymphomas. There are no data on the use of radioimmunotherapy in Waldenstrom's macroglobulinemia. We report a patient with Waldenstrom's macroglobulinemia with transformation to a large B-cell lymphoma, who was treated successfully with iodine 131I-tositumomab. The patient had a complete response to the treatment, including disappearance of any detectable IgM paraprotein. This case report demonstrates the potential for radioimmunotherapy in CD20 positive B-cell malignancies.
Tsai
Donald E
DE
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA. detsai@mail.med.upenn.edu
Maillard
Ivan
I
Downs
Lisa H
LH
Alavi
Abass
A
Nasta
Sunita D
SD
Glatstein
Eli
E
Schuster
Stephen J
SJ
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D016393:Lymphoma, B-Cell / Q000209:etiology / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D012074:Remission Induction; D014055:Tomography, Emission-Computed; D008258:Waldenstrom Macroglobulinemia / Q000150:complications / Q000532:radiotherapy*
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; C119496:tositumomab I-131